Updated Data for First-Line Immunotherapy Combinations Reinforce Their Value in Metastatic Melanoma
OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy in Metastatic Melanoma
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | NEJM
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial - The Lancet Oncology
Phase III CheckMate -067 Trial Demonstrates Superior Progression-Free Survival of Opdivo+Yervoy Regimen or Opdivo Monotherapy vs
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial - The Lancet Oncology
Updated Data for First-Line Immunotherapy Combinations Reinforce Their Value in Metastatic Melanoma
Dual I-O Therapy Efficacy | OPDIVO® (nivolumab)
Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada | SpringerLink
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | NEJM
OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy in Metastatic Melanoma
ESMO 2017: Cost-effectiveness of nivolumab+ipilimumab in first-line treatment of advanced melanoma: Analysis using 28-month overall survival from CheckMate 067
CheckMate 067: Dual Checkpoint Blockade Proves Effective in Advanced Melanoma - The ASCO Post
Cancers | Free Full-Text | LAG3-PD1 or CTLA4-PD1 Inhibition in Advanced Melanoma: Indirect Cross Comparisons of the CheckMate-067 and RELATIVITY-047 Trials
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | NEJM
Updated Data for First-Line Immunotherapy Combinations Reinforce Their Value in Metastatic Melanoma
NEJM on Twitter: "Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (CheckMate 067) https://t.co/0pcpqYVD59 #ESMO17 https://t.co/EpX5KyPgOS" / Twitter
Long-Term Outcomes From CheckMate 067 Nivolumab/Ipilimumab, Nivolumab, or Ipilimumab in Advanced Melanoma - The ASCO Post
Cancers | Free Full-Text | Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma
Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England
Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067 | Journal for ImmunoTherapy of Cancer
NEJM on Twitter: "Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (CheckMate 067) https://t.co/0pcpqYVD59 #ESMO17 https://t.co/EpX5KyPgOS" / Twitter
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | NEJM
